Mycophenolate Mofetil Accord Healthcare (Mycophenolate Mofetil)

The drug inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH), which blocks the synthesis of guanosine nucleotides needed for lymphocyte proliferation. This selective action reduces the activity of T and B cells, dampening the immune response that can damage transplanted organs.

The dosage of Mycophenolate Mofetil Accord Healthcare is determined by the prescribing clinician based on the patient’s transplant type, weight, renal function, and other individual factors. Only a qualified healthcare professional should set the dosing regimen.

Mycophenolate Mofetil is classified as Pregnancy Category D, indicating evidence of fetal risk. It should not be used during pregnancy, and breastfeeding is not recommended because the drug can be excreted in milk and may harm the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Compared with calcineurin inhibitors such as cyclosporine or tacrolimus, Mycophenolate Mofetil offers a different mechanism by targeting lymphocyte proliferation rather than cytokine production. It is often used in combination regimens to provide synergistic immunosuppression while allowing lower doses of each agent, potentially reducing individual drug toxicity.

The product should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the solution in its original packaging until use to maintain stability and sterility.

Mycophenolate Mofetil Accord Healthcare is supplied as an intravenous solution and is administered by slow infusion into a vein under the supervision of a qualified healthcare professional, following the dosing instructions provided by the prescriber.

Serious risks include severe leukopenia, opportunistic infections, hepatic dysfunction, and an increased risk of certain malignancies. Patients should be monitored regularly for blood count changes, liver enzyme elevations, and signs of infection, and any concerning symptoms should be reported promptly.

Mycophenolate Mofetil should not be used in patients with known hypersensitivity to the drug, in pregnant women, or in individuals with uncontrolled infections. Caution is also advised for patients with severe renal or hepatic impairment, and live vaccines should be avoided during therapy.